Loading...
XNAS
JAZZ
Market cap6.68bUSD
Apr 04, Last price  
110.04USD
1D
-8.92%
1Q
-8.73%
Jan 2017
0.93%
IPO
136.34%
Name

Jazz Pharmaceuticals PLC

Chart & Performance

D1W1MN
XNAS:JAZZ chart
No data to show
P/E
11.93
P/S
1.64
EPS
9.22
Div Yield, %
—
Shrs. gr., 5y
2.78%
Rev. gr., 5y
13.48%
Revenues
4.07b
+6.12%
21,442,00044,856,00065,303,00067,514,000128,449,000173,781,000272,277,000585,979,000872,423,0001,172,875,0001,324,803,0001,487,973,0001,618,693,0001,890,922,0002,161,761,0002,363,567,0003,094,238,0003,659,374,0003,834,204,0004,068,950,000
Net income
560m
+35.02%
-85,156,000-59,391,000-138,826,000-184,339,000-6,836,00032,778,000124,984,000288,586,000216,312,00058,387,000329,535,000396,831,000487,848,000447,098,000523,367,000238,616,000-328,954,000-214,139,000414,832,000560,120,000
CFO
1.40b
+27.83%
-52,162,000-57,350,000-81,091,000-130,232,000-15,878,00058,868,000151,596,000249,752,000283,616,000405,765,000531,943,000590,536,000693,087,000798,904,000776,401,000899,648,000778,507,0001,271,977,0001,092,007,0001,395,908,000

Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
URL
https://www.jazzpharma.com/
IPO date
Jan 18, 2012
Employees
2,800
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,068,950
6.12%
3,834,204
4.78%
3,659,374
18.26%
Cost of revenue
445,713
1,285,235
1,130,970
Unusual Expense (Income)
NOPBT
3,623,237
2,548,969
2,528,404
NOPBT Margin
89.05%
66.48%
69.09%
Operating Taxes
(89,769)
(119,912)
(158,645)
Tax Rate
NOPAT
3,713,006
2,668,881
2,687,049
Net income
560,120
35.02%
414,832
-293.72%
(214,139)
-34.90%
Dividends
Dividend yield
Proceeds from repurchase of equity
(311,429)
(269,761)
97,966
BB yield
3.83%
3.04%
-0.98%
Debt
Debt current
45,779
624,401
31,000
Long-term debt
131,593
5,245,885
5,837,017
Deferred revenue
5,039
Other long-term liabilities
6,125,316
104,751
106,812
Net debt
(2,815,492)
4,239,276
4,981,035
Cash flow
Cash from operating activities
1,395,908
1,092,007
1,271,977
CAPEX
(38,070)
(23,962)
(498,194)
Cash from investing activities
(508,195)
(163,062)
(446,230)
Cash from financing activities
20,516
(305,254)
(529,491)
FCF
3,990,771
2,533,923
3,108,713
Balance
Cash
2,992,864
1,626,310
881,482
Long term investments
4,700
5,500
Excess cash
2,789,416
1,439,300
704,013
Stockholders' equity
179,686
36,570
(391,862)
Invested Capital
10,163,041
9,596,792
9,372,870
ROIC
37.58%
28.14%
28.06%
ROCE
32.88%
24.32%
25.47%
EV
Common stock shares outstanding
66,007
72,066
62,539
Price
123.15
0.12%
123.00
-22.79%
159.31
25.05%
Market cap
8,128,762
-8.30%
8,864,118
-11.03%
9,963,088
31.01%
EV
5,313,270
13,103,394
14,944,123
EBITDA
4,283,304
3,187,665
3,157,875
EV/EBITDA
1.24
4.11
4.73
Interest
238,097
289,438
288,242
Interest/NOPBT
6.57%
11.36%
11.40%